LONDON/NEW YORK (Reuters) - The "war on sugar" being waged by governments and consumers to combat public health emergencies like diabetes is slowing growth in global demand, which along with other factors could signal a fundamental shift in consumption ahead.
KISUMU, Kenya (Reuters) - President Donald Trump's dramatic expansion of a policy blocking U.S. aid to organizations offering abortion services will have one sure result, say medical workers in this city: more abortions.
FRANKFURT (Reuters) - Germany's highest court ruled on Tuesday that a father could have his child vaccinated according to a schedule recommended by authorities even though the mother of the girl is opposed.
LONDON (Reuters) - Britain's competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies.
LONDON (Reuters) - AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroid drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year.
(Reuters) - Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.
WASHINGTON (Reuters) - The Trump administration asked on Monday that a major federal court case weighing the fate of the Obamacare cost-sharing subsidies be put on hold again, leaving billions of dollars in payments to insurers up in the air for 2017 and 2018.
(Reuters) - The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday.
COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of "phenomenal" performance by its new anti-obesity injection Saxenda, a senior company official said on Monday.